Comparative genomic hybridization

Global Molecular Cytogenetics Market Research Report 2023: Rising Adoption of Array Based CGH to Spur Overall Demand - Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 26, 2023
Research, Science, Age, Developed country, Growth, Genetic, Personalized medicine, Prevalence, Development, Incidence, Software, Genetic disorder, Fluorescence in situ hybridization, Fluorescence, Comparative genomic hybridization, Real, COVID-19, CGH, Molecular Cytogenetics, Molecular biology, Abbott Laboratories, Thermo Fisher Scientific, Total, Table, Cornerstone, Consumables, Fine chemical, Retail, Agriculture, Tourism, Video game, Karyotype, Immunohistochemistry, Revenue, Cancer, Instrument

The "Molecular Cytogenetics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Molecular Cytogenetics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • This market encompasses various facets, including Molecular Cytogenetics itself, Consumables, Instruments, Software & Services, as well as techniques like CGH (Comparative Genomic Hybridization), FISH (Fluorescence In Situ Hybridization), Immunohistochemistry, Karyotyping, and other methods.
  • The U.S. market, with an estimated worth of US$794.6 million in 2022, holds a prominent position within this market.
  • This report provides an extensive analysis of the global Molecular Cytogenetics market, furnishing insights into annual revenues, historical patterns, and future forecasts spanning from 2014 to 2030.

KromaTiD Launches directional Genomic Hybridization (dGH) in-Site™ DNA Probes, Expanding Access for Cell and Gene Therapy Research Programs

Retrieved on: 
Thursday, July 20, 2023
FISH, CD19, Telomere, QC, NGS, PDCD1, Single-cell analysis, CIITA, Research, ISH, Genome, CAR, Comparative genomic hybridization, Centromere, DdPCR, DGH, IND, Antibiotics, Microscope

KromaTiD dGH™ products and services are widely used to assess genomic structural variation and gene-editing outcomes that cannot be identified using next generation sequencing (NGS) or fluorescence in-situ hybridization (FISH).

Key Points: 
  • KromaTiD dGH™ products and services are widely used to assess genomic structural variation and gene-editing outcomes that cannot be identified using next generation sequencing (NGS) or fluorescence in-situ hybridization (FISH).
  • Making these dGH in-Site™ probes commercially available enables research institutes and core labs as well as biopharma and pharmaceutical companies to economically design and execute dGH in-Site™ assays in-house.
  • "The key difference between dGH™ and other in-situ hybridization (ISH) methods is the outcome: dGH ™provides a much deeper data set than any other genomic ISH technique," explains KromaTiD Chief Technology Officer, Christopher Tompkins.
  • This is extremely valuable at all stages of a cell and gene therapy program, from research to preclinical to IND filing to QC testing of drug product."

Worldwide Market for Life Science Instrumentation to 2026: Market Opportunities, Expected Growth and Important Trends - ResearchAndMarkets.com

Retrieved on: 
Friday, January 20, 2023
Health, Other Health, Comparative genomic hybridization, Analytic, Cell, Flow cytometry, HCS, Biologically based mental illness, Molecular biology, DNA, Peptide, Synthesizer, NGS, PCR, Biochemistry, SPR, Protein, RNA, Growth, Therapy, Oligonucleotide, Gene expression, Drug discovery, Animal, Laboratory, Global Assessment Report on Biodiversity and Ecosystem Services, Disease, Polymerase chain reaction, Electrophoresis, Global Assessment of Functioning, Electrophysiology, Metagenomics, CGH, Research, Medical device, Fine chemical, Vaccine, Microscope, Medical imaging

The "The Worldwide Market for Life Science Instrumentation, 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Worldwide Market for Life Science Instrumentation, 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The Worldwide Market for Life Science Instrumentation, 2021- 2026 is designed to provide total market knowledge for every significant life science instrumentation category.
  • This comprehensive report details the market opportunity expected growth and important trends in these essential instruments for manufacturing, control, research and development of biopharmaceutical therapies, as well as instruments used for basic life science research.
  • This section is directly extracted from the Global Assessment Report: The Analytical and Life Science Instrumentation Industry.

Gene Amplification Technologies Market Report 2023-2033

Retrieved on: 
Friday, December 9, 2022
Sequence, Genome, NGS, Research, Single cell, DNA, Gene amplification, PCR, Genomics, Molecular diagnostics, Rest, Region, Investment, COVID-19, Growth, Data analysis, Key market, Amplification, HGP, Medication, Market, Table, Neoplasm, SNP, Comparative genomic hybridization, Recession, Biotechnology, Antibiotics, Marketing, Oil

NEW YORK, Dec. 9, 2022 /PRNewswire/ -- Gene Amplification Technologies Market Report 2023-2033: Forecasts by Sample Type (Single Cell, Formalin-Fixed and Paraffin-Embedded (FFPE)), by End-user (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Other), by Business Type (Gene Amplification Kits and Reagents, Gene Amplification Instruments, Gene Amplification Services, Gene Amplification Ancillaries), by Application (Hybridization Application, Whole Genome Amplification, Exome Sequencing Amplification, SNP Genotyping Arrays, Array CGH), by Technology (PCR-based Amplification, Loop-mediated Isothermal Amplification, Nucleic Acid Sequence Based Amplification, Strand Displacement Amplification, Multiple Displacement Amplification, Other) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis

Key Points: 
  • NEW YORK, Dec. 9, 2022 /PRNewswire/ -- Gene Amplification Technologies Market Report 2023-2033: Forecasts by Sample Type (Single Cell, Formalin-Fixed and Paraffin-Embedded (FFPE)), by End-user (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Other), by Business Type (Gene Amplification Kits and Reagents, Gene Amplification Instruments, Gene Amplification Services, Gene Amplification Ancillaries), by Application (Hybridization Application, Whole Genome Amplification, Exome Sequencing Amplification, SNP Genotyping Arrays, Array CGH), by Technology (PCR-based Amplification, Loop-mediated Isothermal Amplification, Nucleic Acid Sequence Based Amplification, Strand Displacement Amplification, Multiple Displacement Amplification, Other) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis
    The Gene Amplification Technologies Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics.
  • Where is the gene amplification technologies market heading and how can you ensure you are at the forefront of the market?
  • This report tells you TODAY how the gene amplification technologies market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising gene amplification technologies prices and recent developments.

Global Cytogenetics Markets, Technology, & Competitive Landscape Report 2021 with Profiles of 70 Companies - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 18, 2021
Technology, Biotechnology, Nanotechnology, Health, CGH, Chromosome, Fort Dix, Single-nucleotide polymorphism, Optical flow, Technology, Magnetic resonance imaging, Biomarker, FISH, PCR, Diagnosis, Disease, SWOT, Nanotechnology, Cancer, SPM, AFM, Human, Fluorescence, Therapy, PNA, Genetic variation, Molecular imaging, Lists of diseases, Hybridization probe, DNA, Organic acid, Infection, MRI, Optical mapping, PET, In situ hybridization, Drug discovery, Company, Genetic disorder, Real-time polymerase chain reaction, Comparative genomic hybridization, Pharmaceutical industry, Medical imaging, Microscope

This report deals with cytogenetics in a broader sense rather than the classical use mainly to describe the chromosome structure and identify abnormalities related to disease.

Key Points: 
  • This report deals with cytogenetics in a broader sense rather than the classical use mainly to describe the chromosome structure and identify abnormalities related to disease.
  • The scope of cytogenetics includes several technologies besides fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and multicolor FISH.
  • Molecular cytogenetics includes the applications of nanobiotechnology, microarrays, real-time polymerase chain reaction (PCR), in vivo imaging, and single molecule detection.
  • The report includes summary profiles of 70 companies relevant to cytogenetics along with their 80 collaborations.

Breast Cancer Diagnostics Global Market Report 2021: COVID-19 Growth and Change to 2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, September 13, 2021
Biotechnology, Health, Oncology, Medical Devices, Incidence, Exact sciences, Siemens, Breast cancer, Biopsy, Technology, EGFR, Patient, Growth, BRCA, Southwest Medical Center, Risk, Gene expression, FISH, Disease, IHC, Genomic Health, Breast, Fujifilm, In situ hybridization, Death, COVID-19, GE Healthcare, Abbott Laboratories, Comparative genomic hybridization, Mammography, Hospital, Organization, Association for Molecular Pathology v. Myriad Genetics, Inc., Diagnosis, Acquisition, CGH, Woman, Cancer, Hologic, Medical imaging, Dietary supplement

The "Breast Cancer Diagnostics Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Breast Cancer Diagnostics Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The breast cancer diagnostics market consists of sales of breast cancer diagnostic devices and related services by entities (organizations, sole traders and partnerships) that produce breast cancer diagnostics devices.
  • Therefore, the high-cost diagnosis of breast cancer makes the process a distant option and hinders the growth of the breast cancer diagnostics market.
  • The increasing incidence of breast cancer is expected to drive the growth of the breast cancer diagnostics market.

Digital PCR Market to Reach USD 1,139.9 Million By 2028, Growing At A CAGR Of 9.1% - Valuates Reports

Retrieved on: 
Thursday, September 9, 2021

BANGALORE, India, Sept. 9, 2021 /PRNewswire/ -- Digital PCR Market by Technologies (Droplet Digital PCR, Chip Based Digital PCR and BEAMing Digital PCR), Product Type (Digital PCR Systems, Consumables & Reagents, and Software & Services), Application (Research, Clinical Diagnostics, and Forensic & Others), and End User (Pharmaceuticals & Biotechnology Industries, Clinical Diagnostic Laboratories, and Universities & Other Organizations): Global Opportunity Analysis and Industry Forecast, 2021-2028. It is published in Valuates Reports under the  Medical Devices & Equipment Category.

Key Points: 
  • The globaldigital polymerase chain reaction marketgenerated USD 508.8 million in 2020 and is projected to reach USD 1,139.9 million by 2028, growing at a CAGR of 9.1% from 2021 to 2028.
  • Furthermore, technological developments as a result of increased funding for R&D activities are likely to drive Digital PCR market expansion during the forecast period.
  • The growth of the digital PCR market is projected to be fueled by the rising prevalence of infectious diseases and genetic disorders.
  • Digital PCR Market SHARE Analysis:
    Based on technology, the Droplet Digital PCR segment holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.

Digital PCR Market to Reach USD 1,139.9 Million By 2028, Growing At A CAGR Of 9.1% - Valuates Reports

Retrieved on: 
Thursday, September 9, 2021

The globaldigital polymerase chain reaction marketgenerated USD 508.8 million in 2020 and is projected to reach USD 1,139.9 million by 2028, growing at a CAGR of 9.1% from 2021 to 2028.

Key Points: 
  • The globaldigital polymerase chain reaction marketgenerated USD 508.8 million in 2020 and is projected to reach USD 1,139.9 million by 2028, growing at a CAGR of 9.1% from 2021 to 2028.
  • Furthermore, technological developments as a result of increased funding for R&D activities are likely to drive Digital PCR market expansion during the forecast period.
  • The growth of the digital PCR market is projected to be fueled by the rising prevalence of infectious diseases and genetic disorders.
  • Digital PCR Market SHARE Analysis:
    Based on technology, the Droplet Digital PCR segment holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.

KromaTiD Announces Launch of dGH SCREEN™ for Unbiased Whole Genome Analysis of Chromosomal Structural Rearrangements

Retrieved on: 
Thursday, September 2, 2021
Patient, Radiation exposure, Genome, Gene editing, NGS, NIST, GLP, Colorado State University, SCREEN, Comparative genomic hybridization, NASA, DNA, CSU, UTMB, University, Company, DGH, CRISPR, Research, Cas9, Colorado, Genomics, De novo, Degenerative disease, Microscope, Antibiotics

dGH SCREEN is built upon KromaTiD's proprietary directional Genomic Hybridization technology, a platform for measuring genomic structure and structural variation.

Key Points: 
  • dGH SCREEN is built upon KromaTiD's proprietary directional Genomic Hybridization technology, a platform for measuring genomic structure and structural variation.
  • Using dGH Screen, researchers worldwide can now visualize the structure of the human genome and discover structural variation in a completely de novo fashion at the unprecedented resolution of 5Kb.
  • "Researchers who rely only on next generation sequencing (NGS) only to discover or detect variation often miss important structural rearrangements to the genome."
  • Erin Cross, KromaTiD's Director of Whole Genome Development and leading the research efforts for dGH Screen, stated, "As an inherently whole genome, single cell method, dGH Screen doesn't just measure consistent structural variation.

KromaTiD Appoints Nathan Wood as Chief Executive Officer

Retrieved on: 
Friday, August 13, 2021
Mutation, NGS, College, Regenerative medicine, Wood, Gene editing, Colorado State University, Degenerative disease, Oregon State University, Life Technologies, Nathan Wood, CEO, Company, Bachelor, Cancer, Biofuel, DNA, Research, Chromosome, Marketing, DGH, Board, Genomics, Growth, Comparative genomic hybridization, Technology, IDT, Danaher, Board of directors, Therapy, University of Houston–Downtown College of Sciences and Technology, Management, Vaccine

LONGMONT, Colo., Aug. 13, 2021 /PRNewswire/ --KromaTiD, Inc. announces that Nathan Wood, will be joining as its Chief Executive Officer.

Key Points: 
  • LONGMONT, Colo., Aug. 13, 2021 /PRNewswire/ --KromaTiD, Inc. announces that Nathan Wood, will be joining as its Chief Executive Officer.
  • Wood replaces Christopher Tompkins, who will assume the role of Chief Technology Officer.
  • He has been an executive and C-level contributor at a number of leading life science companies.
  • KromaTiD, Inc. is a Colorado-based bioscience company dedicated to creating products for disease research, mutation detection and structural analysis of chromosomes.